That was higher than its previous bid of up to $9 billion which sparked a lawsuit from pfizer. Pfizer wins $10 billion bid for metsera, securing entry into the booming obesity drug market Metsera accepted a sweetened offer from.
Maya Singer, mayascherry19 | Linktree
The announcement of the deal signaled an end to the bidding war for metsera between pfizer and novo nordisk, the danish maker of ozempic and wegovy.
The new proposal for the coveted obesity drug developer is more than double the size of pfizer’s original bid and ends a squabble with novo nordisk that had resulted in lawsuits.
Metsera initially agreed to be acquired by pfizer in september for $4.9 billion, with additional cvrs down the line 30, novo nordisk tried to pinch metsera with an $8.5 billion offer Pfizer sued novo to stop the deal, and the two companies made a series of counteroffers, upping the potential windfall for metsera to upwards of $10 billion. The pharmaceutical giant's revised offer, which significantly increased the deal's value, won metsera's board approval, bringing an end to the competitive auction between pfizer and novo nordisk, the maker of.
